Clinical trials: in Ecuador
High-risk Cardiac Patients
Registry Study for the Evaluation of High-risk Cardiac Patients by WILLEM AI-based ECG Platform
The WILLEM Registry is a large-scale, single-group, observational, registry study to collect continuous clinical evidence of Willem in real-world settings.
- Trial name
- WILLEMRegistry (NCT07333547)
- Testing
- Willem AI ECG assessment
- Where
- 5 sites in United States, Ecuador and 1 more
- Volunteers
- 200,000 people, healthy volunteers welcome
- Sponsor
- Idoven 1903 S.L.
Dengue Fever
Study of AT-752 in Patients With Dengue Infection
The Phase 2 study will be conducted in adult patients with confirmed Dengue infection and will investigate safety, PK, and pharmacodynamics (PD) in this population.
- Trial name
- NCT05466240
- Testing
- AT-752
- Where
- 32 sites in Brazil, Colombia and 8 more
- Volunteers
- 21 people
- Sponsor
- Atea Pharmaceuticals, Inc.
Diabetes Mellitus, Type 2
Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications
This study is a test of the safety and effectiveness of two drugs, one for diabetes and one for hypertension, in keeping patients with high lab values of glucose from progressing to frank diabetes and developing cardiovascular…
- Trial name
- Navigator (NCT00097786)
- Testing
- Valsartan 160 mg + nateglinide 60 mg
- Where
- 38 sites in United States, Argentina and 36 more
- Volunteers
- 9,306 people
- Sponsor
- Novartis Pharmaceuticals
Prevention & Control
Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease
The primary objectives of this study are: To determine whether rivaroxaban 2.5 mg twice daily (bid) + aspirin 100 mg once daily (od) compared with aspirin 100 mg od reduces the risk of a composite of myocardial infarction…
- Trial name
- COMPASS (NCT01776424)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Aspirin, Pantoprazole
- Where
- 565 sites in United States, Argentina and 31 more
- Volunteers
- 27,395 people
- Sponsor
- Bayer
Metastatic Breast Cancer
Ph3 Study To Determine Safety,Tolerability&Tumor Response Of Oraxol Compared To Taxol In Metastatic Breast Cancer
To determine the safety and tolerability of Oraxol as compared to IV paclitaxel in metastatic breast cancer
- Trial name
- NCT02594371
- Testing
- Oraxol, IV paclitaxel
- Where
- 45 sites in Argentina, Chile and 8 more
- Volunteers
- 402 people
- Sponsor
- Athenex, Inc.
Metastatic Renal Cell Carcinoma ( mRCC)
A Retrospective Medical Record Review of First-Line Sunitinib Administration Schedules and Outcomes Among Patients With mRCC in Latin America (LA)
To describe real-world demographic and clinical characteristics, treatment characteristics, and clinical outcomes among patients in Latin America who were treated with first-line sunitinib for metastatic renal cell carcinoma and…
- Trial name
- NCT04115189
- Testing
- Sunitinib
- Where
- 7 sites in Argentina, Brazil and 2 more
- Volunteers
- 57 people
- Sponsor
- Pfizer
Breast Cancer
A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment
This two-cohort, open-label, multicenter study will assess the safety, efficacy and tolerability of trastuzumab emtansine in participants with HER2-positive locally advanced breast cancer (LABC) or metastatic breast cancer (mBC)…
- Trial name
- NCT01702571
- Testing
- Trastuzumab Emtansine
- Where
- 300 sites in Argentina, Australia and 41 more
- Volunteers
- 2,185 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Long Term Evaluation of Sarilumab in Rheumatoid Arthritis Patients (SARIL-RA-EXTEND)
Main Study: Primary Objective: Assess the long term safety of sarilumab in participants with rheumatoid arthritis (RA). Secondary Objective: Assess the long term efficacy of sarilumab in participants with RA.
- Trial name
- NCT01146652
- Testing
- SAR153191 (REGN88)
- Where
- 335 sites in United States, Argentina and 38 more
- Volunteers
- 2,023 people
- Sponsor
- Sanofi
Prevention of COVID-19, Safety and Efficacy
A Phase III Clinical Trial to Determine the Safety and Efficacy of ZF2001 for Prevention of COVID-19
A randomized, double-blind, placebo-controlled international multicenter clinical trial design will be adopted. A total of 29,000 subjects aged 18 years and above are planned to be recruited, including 750 subjects aged 18-59…
- Trial name
- NCT04646590
- Testing
- Recombinant new coronavirus vaccine (CHO cell) group
- Where
- 18 sites in China, Ecuador and 3 more
- Volunteers
- 28,904 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Hemophilia A
Non-interventional Post-authorisation Study to Document the Immunogenicity, Safety, and Efficacy of NUWIQ
Prospective, multinational, non-interventional post-authorisation study to collect additional clinical data and to ensure consistency in the long-term between the outcome from pre-authorisation clinical studies (in 135 previously…
- Trial name
- NCT02962765
- Where
- 39 sites in United States, Argentina and 11 more
- Volunteers
- 80 people
- Sponsor
- Octapharma
Lupus Nephritis
AURA-LV: Aurinia Urinary Protein Reduction Active - Lupus With Voclosporin (AURA-LV)
To assess the efficacy of 2 doses of voclosporin compared to placebo in achieving complete remission after 24 weeks of therapy in subjects with active lupus nephritis.
- Trial name
- AURA-LV (NCT02141672)
- Testing
- Voclosporin High Dose, Voclosporin Low Dose
- Where
- 86 sites in United States, Bangladesh and 18 more
- Volunteers
- 265 people
- Sponsor
- Aurinia Pharmaceuticals Inc.
Breast Neoplasms
A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
This multicenter, two-cohort, non-randomized, open-label study will evaluate the safety and tolerability of assisted and self-administered SC Herceptin as adjuvant therapy in participants with early HER2-positive breast cancer…
- Trial name
- SafeHER (NCT01566721)
- Testing
- Herceptin
- Where
- 437 sites in Albania, Algeria and 57 more
- Volunteers
- 2,577 people
- Sponsor
- Hoffmann-La Roche
Stroke, Atrial Fibrillation
GLORIA-AF Registry Program - Second and Third Phases
In this part of the Registry Program patients with non-valvular atrial fibrillation (AF) at risk for stroke are enrolled to characterize the target population and to collect real world data on important outcome events.
- Trial name
- NCT01468701
- Where
- 666 sites in United States, Argentina and 19 more
- Volunteers
- 37,235 people
- Sponsor
- Boehringer Ingelheim
Mercury Poisoning
Pilot Proof of Concept Study of NBMI Treatment of Mercury Intoxication
A randomized, placebo controlled, double blind proof of concept study of NBMI in treatment of mercury intoxication.
- Trial name
- NBMI (NCT02486289)
- Testing
- Emeramide
- Where
- Ecuador
- Volunteers
- 36 people
- Sponsor
- EmeraMed
Osteoarthritis, Arthritis, Rheumatoid
Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis
To determine whether celecoxib is superior to combined therapy with diclofenac and omeprazole in the incidence of clinically significant upper and/or lower gastrointestinal (GI) events in high GI risk subjects with osteoarthritis…
- Trial name
- CONDOR (NCT00141102)
- Testing
- Celecoxib, Diclofenac + Omeprazole
- Where
- 194 sites in Belgium, Brazil and 30 more
- Volunteers
- 4,484 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Ankle Sprain
Open Label Comparative Study On Celecoxib Efficacy And Safety Vs Non-Selective NSAID In Acute Pain Due To Ankle Sprain
To assess the efficacy of celecoxib loading dose of 400mg followed by 200 mg twice a day (BID) versus oral non-selective NSAIDs in acute pain due to ankle sprain.
- Trial name
- NCT00446797
- Testing
- Non-selective NSAIDS, Celecoxib
- Where
- 16 sites in Brazil, Costa Rica and 6 more
- Volunteers
- 278 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Dyslipidemias
A Study Of The Efficacy Of Atorvastatin In Lowering Cholesterol In Latin American Patients With High Cholesterol
The purpose of this study is to determine the percentage of patients who would reach a cholesterol goal after atorvastatin treatment.
- Trial name
- LA ATGOAL (NCT00645151)
- Testing
- Atorvastatin
- Where
- 33 sites in Brazil, Chile and 6 more
- Volunteers
- 512 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Diabetic Peripheral Neuropathic Pain (DPN), Postherpetic Neuralgia (PHN)
Pregabalin Treatment Of Peripheral Neuropathic Pain Associated With Diabetic Peripheral NeP (DPN), Postherpetic Neuralgia (PHN), HIV-related NeP (HIV), and Chemotherapy Induced NeP
Management of neuropathic pain associated with diabetic peripheral neuropathy, post-herpetic neuralgia, human immunodeficiency virus-related peripheral neuropathy, and chemotherapy induced peripheral neuropathy.
- Conditions
- Diabetic Peripheral Neuropathic Pain (DPN), Postherpetic Neuralgia (PHN), HIV-related Neuropathic Pain (HIV), Chemotherapy Induced Neuropathic Pain
- Trial name
- NCT00407511
- Testing
- Pregabalin
- Where
- 11 sites in Colombia, Ecuador and 3 more
- Volunteers
- 121 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Diabetic Neuropathy, Painful
A Study To Evaluate Pregabalin In Patients With Painful Diabetic Peripheral Neuropathy (DPN)
A study of pregabalin efficacy and safety in a racially and culturally diverse group of subjects with painful diabetic peripheral neuropathy (DPN).
- Trial name
- NCT00156078
- Testing
- pregabalin
- Where
- 35 sites in Argentina, Brazil and 17 more
- Volunteers
- 450 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Covid-19, Sars-CoV2
Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients Infected by SARS-Cov-2 With COVID-19
This is a two-arm, open-label, randomized, phase 2, controlled center study to assess the safety and efficacy of Viusid and Asbrip in patients with mild to moderate symptoms of respiratory disease caused by 2019 coronavirus…
- Conditions
- Covid-19, Sars-CoV2, Diabete Mellitus, Cardiopathy
- Trial name
- NCT04407182
- Testing
- Viusid and Asbrip
- Where
- Ecuador
- Volunteers
- 60 people
- Sponsor
- Catalysis SL